News | January 31, 2025
Biocon posts Q3 FY25 PAT at Rs. 25 Cr
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
Subscribe To Our Newsletter & Stay Updated
